bAriatric sUrgery Registration in wOmen of Reproductive Age
Avainsanat
Abstrakti
Kuvaus
The investigators aim to develop guidelines or recommendations for the management of pregnancies after bariatric surgery based on large-scale prospective research.
The investigators want to:
1. investigate pregnancy outcomes of women with a history of bariatric surgery according to procedure, interval between surgery and conception, weight change after surgery and during pregnancy and nutritional status, taking into account possible confounding factors such as economic status, alcohol and tobacco use, sleep duration, psychological factors (anxiety and depression) and quality of life
2. determine the incidence of nutritional deficiencies in (pregnant) women of reproductive age after bariatric surgery.
3. evaluate the effect of bariatric surgery in (morbidly) obese women of reproductive age on anthropometry, fertility, sexuality, co-morbidities, use of medication and contraceptives, pregnancy outcomes, quality of life, psychological factors (anxiety and depression), blood biochemical parameters (nutritional status), food intake and physical activity
4. examine breastfeeding practices (intention, initiation, duration) and breast milk composition in women with a history of bariatric surgery
The study is a multicentric prospective cohort study with UZ Leuven as the coordinating central cite and AZ St Jan Brugge (obesity clinic and obstetric clinic), AZ St Lucas Brugge (obstetric clinic), AZ St Nikolaas St Niklaas (obesity clinic), UZ Gent (obesity clinic and obstetric clinic), AZ St Augustinus Wilrijk (obstetric clinic) and CHRH Mons Hainaut (obesity clinic and obstetric clinic) as local sites.
The design for the breast milk analyses is longitudinal and will, for practical reasons, only be initiated in UZ Leuven and UZ Gent. The investogators will collect a breast milk sample of 10 ml on day four of the postpartum and then weekly by the participants at home until the routine 6 week postpartum consultation.
Women will be included in one of the following four inclusion moments (IM):
- Before surgery (women of reproductive age with morbid obesity) (IM1)
- After surgery and not being pregnant (IM2)
- Before 15 weeks of gestation (IM3)
- Day 3 of 4 of the postpartum for breast milk analyses (IM4)
A simple, user-friendly website will be used to simplify the collection and entry of data and to create a large database. Researchers will be able to directly and continuously register patient data (replacing paper forms) and participants will be able to complete the questionnaires online. The database will be available via a secure online login. Participating researchers will only have access to their own patient database.
For breast milk analyses, the investigators wil collect a sample of 10 ml during the first feeding moment (between 8 am and 11am) on day four of the postpartum manually or by use of a vacuum pump. Each sample is divided into two different recipients. One part of the sample is frozen immediately in the freezer at -20 °C. The rest of the sample will immediately be heated to +40 °C by use of a bottle warmer. As soon as the sample is heated, it will be ultrasonically analyzed with the MIRIS Sonicator® in order to ensure that the sample is homogeneous. Immediately afterwards, the sample is analyzed with the Human Milk Analyzer (HMA) (MIRIS ®, Uppsala, Sweden) for fat (g/100 ml), proteins (g/100 ml), carbohydrates (g/100 ml), dry matter (g/100 ml) and energy (kcal/100ml). The samples that are being collected at the participants' homes will be frozen at -20° and afterwards analyzed with the HMA.
There are eleven measurement points:
T0 = baseline T1 = pre-operative T2 = 3 weeks post-operative T3 = 3 months post-operative T4 = 6 months post-operative T5 = 12 of x months post-operative T6 = first trimester pregnancy T7 = second trimester pregnancy T8 = third trimester pregnancy T9 = pregnancy T10 = 6 weeks postpartum T11 = 6 months postpartum The number of measurements varies according to the moment of inclusion.
1. Demographical data will be collected at (T0) (participant self-reporting). Age, nationality, ethnicity, marital status, family status, educational level, employment status and profession wil be questioned.
2. Anthropometric data, including body weight, waist circumference, hip circumference and body fat percentage (if measured) are collected at all measurement points and will be recorded by the researcher. The body length is only questioned at the first measurement. Body height and body weight will be used to calculate the Body Mass Index (kg/m²) at each measurement point.
3. During the first measurement the investigators will ask for past medical conditions (reported by the researcher) and obstetric history (gravidity, parity, abortion - self-report participant);
4. The type of procedure, date of surgery and institute of the surgeon will be recorded by the investigators during the first measurement (Reported by researcher). Potential problems or complications will be reported at the next measurement points. (T1-T5).
5. Current medical conditions (eg hypertension) will be reported at each measurement point, together with the used medication (Reported by the researcher).
6. The nutritional status of the participant will be assessed by the investigators on the basis of biochemical parameters in the venous blood. The nutritional status of the newborn will be assessed on the basis of biochemical parameters in the venous umbilical cord blood.
(total protein and albumin, fasten glucose level, fat soluble vitamins A, 25 -hydroxy- vitamin D, vitamin E and vitamin K1, water soluble vitamins B1, vitamin B12 and folate (in the serum and red blood cells (RBC), iron , (+ transferrin, transferrin saturation, ferritin ), calcium, zinc and magnesium, hematology (hemoglobin, hematocrit and RBC count, mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), mean corpuscular volume (MCV)), coagulation (prothrombin time (PT) and activated partial thromboplastin time (aPTT)).
During measurement time T1, T3, T4, T5, a blood sample will be taken at the department of endocrinology and on T6, T7, T9 and T10 at the department of obstetrics-gynecology.
7. Investigators will ask the participants about alcohol, tobacco and sleeping habits (self-report participant). The alcohol consumption will be asked by using the AUDIT-C questionnaire (Alcohol Abuse Disorder Identification Test). If the participant smokes, the amount of cigarettes or other tobacco products that are smoked daily will be recorded.
At the beginning of pregnancy, the participant will be asked whether alcohol and tobacco use have changed. Finally, the sleep duration will also be determined.
8. The food intake will be measured during three days (of which at least 1 day in the weekend), on the basis of a 3-day food diary (self-report participant). The intake of supplements is also questioned (self-report participant).
9. Physical activity will be measured by use of the Kaiser Physical Activity Survey (KPAS), a modified version of the Baecke physical activity questionnaire, which was specifically designed to assess the physical activity in women. The KPAS assesses different domains of physical activity (household /family care activities, professional activities, activities of daily life and sports/exercise). The KPAS was validated for both pregnant and non-pregnant women.
10. The Moorehead-Ardelt Quality of Life Questionnaire II (MA QoLQII) will be used both pre-and postoperatively to assess the quality of life (self-report participant). This validated questionnaire is part of the Bariatric Analysis and Reporting Outcome System (BAROS). The MA QoLQII has been validated in an obese population and can be used for bariatric surgery.
11. The Self-Rating Questionnaire will be used to assess the psycho-social condition of the participant. This is a Dutch-validated questionnaire to measure anxiety, based on the American "State-Trait Anxiety Inventory" version Y of Spielberger (35). The questionnaire included two separated self- questionnaires in which two different concepts can be measured: state anxiety and trait anxiety. The Edinburgh Depression Scale (EDS), a validated 10-item questionnaire, will be used to measure depression during pregnancy and postpartum (self-report participant).
12. A questionnaire will be used to record the menstrual cycle (self-report participant). The menstrual cycle's length, duration of bleeding, number of periods per year, the pattern of the menstrual cycle and the presence of amenorrhea or oligomenorrhea will be assessed. The questionnaire is administered at T1, T4 and T5.
13. Pregnancy intention is asked in non-pregnant women (self-report participant) at the first measurement point (T0).
14. The use of contraceptives, which also examines the therapy adherence, is also questioned (self-report participant). The questionnaire is administered at T1, T4 and T5.
15. Sexuality will be questioned to determine the relationship with fertility and the interval between surgery and pregnancy (self-report participant). The questionnaire will be completed at T1, T4 and T5.
16. Clinical pregnancy outcomes of the mother will be questioned each pregnancy trimester (T6-T8) (Reported by the researcher) e.g. conception method, blood pressure, gestational age, gestational diabetes, pre-eclampsia, pregnancy-induced hypertension, clinical problems, etc. The results of the fetal ultrasounds will also be collected during each pregnancy trimester (T6-T8). During childbirth (T9) the duration of pregnancy, labor and delivery method will be questioned. The parameters of the newborn, including gender, birth weight, birth length, head circumference, Apgar scores, admission to the neonatal intensive care unit (NICU) and any complication will be recorded (T9). Finally, postpartum data such as hemoglobin, prescribed supplements, breastfeeding, or any other problems will be recorded.
17. A structured questionnaire about breastfeeding practices, developed by Guelinckx et al. (2011), will be used at 6 months postpartum (T11) (self-report participant). This questionnaire consists of 11 questions including the intention to breastfeed, breastfeeding initiation, duration of (exclusive) breastfeeding and the reasons to stop with breastfeeding.
Päivämäärät
Viimeksi vahvistettu: | 09/30/2016 |
Ensimmäinen lähetys: | 07/22/2015 |
Arvioitu ilmoittautuminen lähetetty: | 08/02/2015 |
Ensimmäinen lähetetty: | 08/03/2015 |
Viimeisin päivitys lähetetty: | 10/27/2016 |
Viimeisin päivitys lähetetty: | 10/30/2016 |
Todellinen opintojen alkamispäivä: | 06/30/2012 |
Arvioitu ensisijainen valmistumispäivä: | 08/31/2017 |
Arvioitu tutkimuksen valmistumispäivä: | 08/31/2017 |
Ehto tai tauti
Vaihe
Kelpoisuusehdot
Tutkimukseen soveltuvat iät | 18 Years Vastaanottaja 18 Years |
Sukupuolet, jotka ovat kelpoisia tutkimukseen | Female |
Näytteenottomenetelmä | Probability Sample |
Hyväksyy terveelliset vapaaehtoiset | Joo |
Kriteeri | Women will be included in one of the following four inclusion moments (IM): - Before surgery (women of reproductive age with morbid obesity) (IM1) - After surgery and not being pregnant (IM2) - Before 15 weeks of gestation (IM3) - Day 3 of 4 of the postpartum for breast milk analyses (IM4) Inclusion and exclusion criteria: 1. IM1 Inclusion criteria: - Women - Age between 18 and 45 years - planning bariatric surgery Exclusion criteria: - Infertile (eg, hysterectomy, menopause, etc.) 2. IM2 Inclusion criteria: - Women - Age between 18 and 45 years - A bariatric surgery in the past Exclusion criteria: - Infertile (eg, hysterectomy, menopause, etc.) 3. IM3 Inclusion criteria: - Women - Age between 18 and 45 years - A bariatric surgery in the past - <15 weeks pregnant Exclusion criteria: - Recruitment after 15 weeks of gestation 4. IM4 Inclusion criteria: - Women - Age between 18 and 45 years - A bariatric surgery in the past - Gestational age between 37 and 42 weeks - Giving birth of a viable child (singleton) - Breastfeeding on day 3 of the postpartum Exclusion criteria: - Intake of the following drugs during lactation: psychotropic drugs, cytotoxic drugs, beta-blockers, dopamine agonists, aspirin, antihistamines, ergotamine, lithium, phenindione, barbiturates, anticonvulsants and sulfasalazine - Diabetes mellitus or diabetes mellitus gravidarum - Newborn admitted to the NICU (no rooming-in) - Uncertainty if milk production is sufficient to meet the needs of the baby (in consultation with the midwife) |
Tulokset
Ensisijaiset tulosmittaukset
1. Gestational weight gain [Birth]
2. Gestational length [Birth]
3. Surgical complications during pregnancy [up to birth]
4. Gestational diabetes mellitus [up to birth]
5. Hypertensive disorders [up to birth]
6. Birth weight [Birth]
Toissijaiset tulosmittaukset
1. Quality of life [preoperatively, postoperatively (6 and 12mo), pregnancy trimester 1 (12w), 2 (20-24w) and 3 (28-32w) and postpartum period (6w and 6 mo)]
2. Breast milk fat content [weekly from day 3-4 after delivery until week 6 after delivery]
3. Contraception [baseline, postoperatively (6 and 12mo)]
4. Physical activity [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w), 2 (20-24w) and 3 (28-32w) and postpartum period (6 mo)]
5. Dietary intake [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w), 2 (20-24w) and 3 (28-32w) and postpartum period (6 mo)]
6. Sleeping habits [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w), 2 (20-24w) and 3 (28-32w) and postpartum period (6 mo)]
7. Breastfeeding practices [Postpartum period (6mo)]
8. Anxiety [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 3 (28-32w) and postpartum period (6w and 6 mo)]
9. Depression [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 3 (28-32w) and postpartum period (6w and 6 mo)]
10. Alcohol use [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w), 2 (20-24w) and 3 (28-32w) and postpartum period (6 mo)]
11. Smoking habits [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w), 2 (20-24w) and 3 (28-32w) and postpartum period (6 mo)]
12. Sexuality [baseline, postoperatively (6 and 12mo)]
13. Total blood count [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)]
14. Vitamin A [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)]
15. 25-OH-vitamin D [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)]
16. vitamin K1 [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)]
17. Vitamin B-12 [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)]
18. Folate [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)]
19. Coagulation [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)]
20. Glucose [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)]
21. Zinc [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)]
22. Anemia [baseline, postoperatively (6 and 12mo), pregnancy trimester 1 (12w) and 2 (20-24w) and postpartum period (6w)]
23. Breast milk protein content [weekly from day 3-4 after delivery until week 6 after delivery]
24. Breast milk carbohydrate content [weekly from day 3-4 after delivery until week 6 after delivery]
25. Breast milk energy content [weekly from day 3-4 after delivery until week 6 after delivery]
26. Mode of delivery [Birth]
27. Apgar score [Birth (2-5-10 minutes)]
28. Body weight [baseline, post-operatively (3w, 3, 6 and 12mo), pregnancy trimester 1 (12w), 2 (20-24w), and 3 (28-32w) and the postpartum period (6w and 6mo)]
Muut lopputulokset
1. Maternal age [baseline]
2. Nationality [baseline]
3. Family status [baseline]
4. Educational level [baseline]
5. Profession [baseline]
6. Marietal status [baseline]
7. body mass index [baseline]